Lundbeck's Carnexiv injection --
an orally administered replacement therapy for short-term use to treat adults with specific types of seizures -- has been
approved by the U.S. Food and Drug Administration.
The FDA has previously granted Carnexiv Orphan Drug
Designation due to the drug’s ability to treat seizures.
Carnexiv will be the
first intravenous formulation made available that is an antiepileptic drug carbamazepine.
“Carbamazepine is very difficult to make as an aqueous-based
injectable formulation, which means that doctors have not had an IV formulation
of the drug available when needed. This approval is the result of years of work
to create a novel and stable injection formulation to support patients who need
an alternative to oral carbamazepine,” University of Minnesota College of
Pharmacy’s Center of Orphan Drug Research Director James Cloyd said.
“We’re proud to partner with Lundbeck and appreciate the company's dedication
to overcoming development challenges and making this therapy option available
for patients and clinicians.”
Lundbeck has plans to release Carnexiv commercially in the
U.S. early next year.
FDA approves Lundbeck’s Carnexiv injection
Alerts Sign-up